MC

445.15

+0.33%↑

SANES

6.915

+0.12%↑

ALV

341.6

-0.23%↓

BNP

75.89

-0.05%↓

BBVA

12.755

-0.7%↓

MC

445.15

+0.33%↑

SANES

6.915

+0.12%↑

ALV

341.6

-0.23%↓

BNP

75.89

-0.05%↓

BBVA

12.755

-0.7%↓

MC

445.15

+0.33%↑

SANES

6.915

+0.12%↑

ALV

341.6

-0.23%↓

BNP

75.89

-0.05%↓

BBVA

12.755

-0.7%↓

MC

445.15

+0.33%↑

SANES

6.915

+0.12%↑

ALV

341.6

-0.23%↓

BNP

75.89

-0.05%↓

BBVA

12.755

-0.7%↓

MC

445.15

+0.33%↑

SANES

6.915

+0.12%↑

ALV

341.6

-0.23%↓

BNP

75.89

-0.05%↓

BBVA

12.755

-0.7%↓

Search

Sartorius Stedim Biotech.

Ouvert

SecteurFinance

205.8 0.83

Résumé

Variation du prix de l'action

24h

Actuel

Min

201.1

Max

207.6

Chiffres clés

By Trading Economics

Revenu

75M

115M

Ventes

-6.7M

745M

P/E

Moyenne du Secteur

92.346

24.617

BPA

1.16

Rendement du dividende

0.34

Marge bénéficiaire

15.498

Employés

9,961

EBITDA

124M

256M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+15.15% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

0.34%

4.23%

Prochains Résultats

22 juil. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

2.4B

19B

Ouverture précédente

204.97

Clôture précédente

205.8

Sentiment de l'Actualité

By Acuity

39%

61%

141 / 538 Classement par Finance

Score Technique

By Trading Central

Confiance

Bullish Evidence

Sartorius Stedim Biotech. Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

26 juin 2025, 23:49 UTC

Résultats

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

26 juin 2025, 22:19 UTC

Acquisitions, Fusions, Rachats

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

26 juin 2025, 21:30 UTC

Résultats

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

26 juin 2025, 21:07 UTC

Résultats

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

26 juin 2025, 23:49 UTC

Market Talk

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

26 juin 2025, 23:39 UTC

Market Talk

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

26 juin 2025, 23:34 UTC

Acquisitions, Fusions, Rachats

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

26 juin 2025, 23:33 UTC

Acquisitions, Fusions, Rachats

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

26 juin 2025, 23:32 UTC

Acquisitions, Fusions, Rachats

Wesfarmers Will No Longer Receive Earnings From BWP Management

26 juin 2025, 23:32 UTC

Acquisitions, Fusions, Rachats

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

26 juin 2025, 23:31 UTC

Acquisitions, Fusions, Rachats

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

26 juin 2025, 23:31 UTC

Acquisitions, Fusions, Rachats

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

26 juin 2025, 23:30 UTC

Acquisitions, Fusions, Rachats

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

26 juin 2025, 23:29 UTC

Acquisitions, Fusions, Rachats

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

26 juin 2025, 23:19 UTC

Acquisitions, Fusions, Rachats

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

26 juin 2025, 22:06 UTC

Résultats

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 juin 2025, 21:15 UTC

Résultats

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

26 juin 2025, 21:07 UTC

Acquisitions, Fusions, Rachats

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

26 juin 2025, 21:07 UTC

Acquisitions, Fusions, Rachats

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

26 juin 2025, 21:07 UTC

Acquisitions, Fusions, Rachats

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

26 juin 2025, 21:07 UTC

Résultats

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 juin 2025, 21:06 UTC

Acquisitions, Fusions, Rachats

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

26 juin 2025, 21:06 UTC

Acquisitions, Fusions, Rachats

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

26 juin 2025, 21:06 UTC

Market Talk

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

26 juin 2025, 21:05 UTC

Acquisitions, Fusions, Rachats

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 juin 2025, 21:05 UTC

Acquisitions, Fusions, Rachats

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 juin 2025, 20:52 UTC

Résultats

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

26 juin 2025, 20:51 UTC

Résultats

Correct: Nike 4Q Net $211M, Not $200M >NKE

26 juin 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26 juin 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

Comparaison

Variation de prix

Sartorius Stedim Biotech. prévision

Objectif de Prix

By TipRanks

15.15% hausse

Prévisions sur 12 Mois

Moyen 234.67 EUR  15.15%

Haut 250 EUR

Bas 210 EUR

Basé sur 9 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

9 ratings

5

Achat

4

Maintien

0

Vente

Score Technique

By Trading Central

202.7 / 211.7Support & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

Strong Bullish Evidence

Sentiment

By Acuity

141 / 538Classement par Finance

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.